Response Biomedical and 3M Collaborate on Infectious Disease Test

New Page 1VANCOUVER, Nov. 29 /CNW/ - Response Biomedical Corp. (TSX-V: RBM) and 3MCompany (NYSE: MMM) through its Medical Division, today announced that the twocompanies have entered into a co-development agreement whereby 3M will fundthe development of a new rapid, point-of-care microbiology test in the area ofinfection prevention based on Response Biomedical's RAMP technology. Theparties intend to enter into a further supply agreement whereby ResponseBiomedical will manufacture and 3M will exclusively market a line ofmicrobiology tests. "3M Medical Division is part of a world company with anextraordinary ability to develop and commercialize promising newtechnologies," states Bill Radvak, President and CEO, Response BiomedicalCorp. "This unique combination of technology and expertise in infectiousdisease testing will help us introduce a broader product portfolio to enhancepatient outcomes and improve productivity for physicians and health careproviders." Conventional diagnosis of infectious diseases is time intensive, andprohibits immediate intervention and early treatment. Clinical infectiousdisease testing at the point-of-care is expected to improve patient outcomesby enabling physicians to make informed medical decisions rapidly. About 3M: 3M is a diversified technology company with 2003 sales of more than$18 billion worldwide. 3M Health Care, the largest of seven major 3Mbusinesses, is dedicated to improving the practice, delivery and outcome ofcare in medical, dental, pharmaceutical, health information and personal caremarkets. 3M Medical Division, part of the 3M Health Care family, is a leaderin medical supplies, with expertise in infection prevention and skin health.For more information, visit www.3M.com. About Response Biomedical: Response Biomedical develops, manufactures and markets rapid on-sitediagnostic tests for use with its RAMP System for clinical and environmentalapplications, providing reliable information in minutes, anywhere, every time.RAMP represents a new paradigm in diagnostic testing, with the potential to beadapted to more than 250 medical and non-medical tests currently performed inlaboratories. The RAMP System consists of a portable fluorescent Reader andsingle-use, disposable Test Cartridges. RAMP tests are commercially availablefor the early detection of heart attack, environmental detection of West Nilevirus, and biodefense applications including the rapid on-site detection ofanthrax, smallpox, ricin and botulinum toxin. The Company has achieved CE Markand its Quality Management System is registered to ISO 13485: 1996 and ISO9000: 2000. Response Biomedical is a publicly traded company, listed on the TSXVenture Exchange under the trading symbol "RBM". For further information,please visit the Company's website at www.responsebio.com. The TSX Venture Exchange has not reviewed and does not acceptresponsibility for the adequacy of the content of the information containedherein. The statements made in this press release may contain certain forward-looking statements that involve a number of risks and uncertainties.Actual events or results may differ from the Company's expectations.For further information: Contact: Don Bradley, Director, Corporate Communications, Response Biomedical Corp., Tel: (604) 681-4101 ext. 202, Email: dbradley@responsebio.com; Brian Korb, Senior Associate, The Trout Group LLC, Tel: (212) 477-9007 ext. 23, mail: bkorb@troutgroup.com